Evidence map›Paper›PMID 36099423›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Associations of Individual and Combined Physical Activity and Body Mass Index Groups with Proinflammatory Biomarkers among Colorectal Cancer Patients.

Caroline Himbert, Christy A Warby, Biljana Gigic, Jennifer Ose, Tengda Lin, Richard Viskochil, Anita R Peoples, Anjelica Ashworth, Petra Schrotz-King, Courtney L Scaife and 17 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 11 institutions in 2 countries.

Caroline HimbertUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-4084-8340
Christy A WarbyHuntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0003-1772-8332
Biljana GigicHeidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-8085-2072
Jennifer OseUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-2030-9676
Tengda LinUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0001-5147-8432
Richard ViskochilUniversity of Massachusetts Boston, Boston, Massachusetts.ORCID 0000-0001-7167-174X
Anita R PeoplesUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-3645-3960
Anjelica AshworthHuntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0002-9676-7702
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Germany.ORCID 0000-0003-4339-3492
Courtney L ScaifeUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-2497-4961
Jessica N CohanUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-5461-4716
Jolanta JedrzkiewiczUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-9408-3139
Peter SchirmacherHeidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-0950-3339
William M GradyFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-0129-7809
Stacey A CohenFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-6207-9856
Mukta KraneFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-4872-1061
Jane C FigueiredoCedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-8040-3341
Adetunji T ToriolaWashington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-1079-2606
Erin M SiegelH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-1779-2510
David ShibataUniversity of Tennessee Health Science Center, Memphis, Tennessee.ORCID 0000-0002-5670-423X
June L RoundUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-7158-9874
Lyen C HuangUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0002-8605-2631
Christopher I LiFred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-1543-0743
Martin SchneiderHeidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0001-8215-7359
Alexis UlrichRheinland Klinikum Neuss Lukas Krankenhaus, Neuss, Germany.ORCID 0000-0003-1469-2186
Sheetal HardikarUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0003-0292-6168
Cornelia M UlrichUniversity of Utah, Salt Lake City, Utah.ORCID 0000-0001-7641-059X
University of Utah · USUniversity of Washington · USHeidelberg University · DEHuntsman Cancer Institute · USCedars-Sinai Medical Center · USLukaskrankenhaus · DEMoffitt Cancer Center · USNational Center for Tumor Diseases · DEUniversity of Massachusetts Boston · USUniversity of Missouri–St. Louis · USUniversity of Tennessee Health Science Center · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagusU2CCA271902 · NCI · FRED HUTCHINSON CANCER CENTER · PI Cecilia C Yeung · 2022 to 2026
$5.3M
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7M
Vascular Health and Risk Factors in Children with Down SyndromeKL2TR002539 · NCATS · UNIVERSITY OF UTAH · PI MURTAUGH, MAUREEN A, NYGAARD, INGRID E · 2018 to 2022
$4.3M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyR01CA211705 · NCI · UNIVERSITY OF UTAH · PI LASTAYO, PAUL C, ULRICH, CORNELIA M · 2017 to 2021
$2.2M
Diabetes, Medications and the Cost-Effectiveness of Screening for Colorectal NeoplasiaK07CA222060 · NCI · UNIVERSITY OF UTAH · PI HARDIKAR, SHEETAL · 2018 to 2022
$791k
Identifying Barriers to Patient-Centered Decision Making for Older Adults with DiverticulitisR03AG067994 · NIA · UNIVERSITY OF UTAH · PI COHAN, JESSICA N · 2020 to 2021
$305k
NCATS NIH HHS KL2 TR002539NCI NIH HHS K07 CA222060NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA211705NCI NIH HHS R01 CA254108NCI NIH HHS U01 CA206110NCI NIH HHS U01 CA272529NCI NIH HHS U2C CA271902NIA NIH HHS R03 AG067994
6 · The paper itself

Abstract

backgroundPhysical activity and obesity are well-established factors of colorectal cancer risk and prognosis. Here, we investigate associations of individual and combined physical activity and body mass index (BMI) groups with proinflammatory biomarkers in colorectal cancer patients.

methodsSelf-reported physical activity levels were classified as "active" (≥8.75 MET-hours/week) versus "inactive" (<8.75 MET-hours/week) in n = 579 stage I-IV colorectal cancer patients enrolled in the ColoCare Study. BMI [normal weight (≥18.5-<25 kg/m2), overweight (≥25-<30 kg/m2), and obese (≥30 kg/m2)] was abstracted from medical records. Patients were classified into four combinations of physical activity levels and BMI. Biomarkers [C-reactive protein (CRP), SAA, IL6, IL8, and TNFα] in presurgery serum samples were measured using the Mesoscale Discovery Platform. Regression models were used to compute relative percent differences in biomarker levels by physical activity and BMI groups.

results"Inactive" patients had non-statistically significant higher IL6 levels compared with "active" patients (+36%, P = 0.10). "Obese" patients had 88% and 17% higher CRP and TNFα levels compared with "normal weight" patients (P = 0.03 and 0.02, respectively). Highest CRP levels were observed among "overweight or obese/inactive" compared with "normal weight/active" patients (P = 0.03).

conclusionsWe provide evidence of associations between individual and combined physical activity and BMI groups with proinflammatory biomarkers. Although BMI was identified as the key driver of inflammation, biomarker levels were higher among "inactive" patients across BMI groups. IMPACT: This is the largest study in colorectal cancer patients investigating associations of energy balance components with inflammatory biomarkers. Our results suggest that physical activity may reduce obesity-induced inflammation in colorectal cancer patients and support the design of randomized controlled trials testing this hypothesis.

Indexed as

Colorectal NeoplasmsOverweightBiomarkersBody Mass IndexC-Reactive ProteinExerciseHumansInflammationInterleukin-6ObesityTumor Necrosis Factor-alphaBiomarkersC-Reactive ProteinInterleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID36099423
PMCPMC9729421
OpenAlexW4295755135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.